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Summary In the BUPA study, a prospective study of 22,000 men attending a screening centre in London, the
mean serum cholesterol level of the 267 men who developed cancer was 6.66mmoll-1, not significantly
different from the mean level of 6.72mmoll-1 among the 525 unaffected controls matched for age, smoking
history and the calendar quarter of their attendance at the screening centre. There was, however, a significant
difference in serum cholesterol levels among men who were diagnosed as having cancer less than 2 years after
the date of blood collection (6.49mmol P- for the 116 cancer subjects and 6.78mmol l- for the 224 controls
(P=0.02)) but not in men who developed cancer 2-11 years after blood collection (6.79mmol P- for the 151
cancer subjects and 6.68 mmol l- for the 301 controls). The observation that the association between low
serum cholesterol and cancer was confined to men in whom a diagnosis of cancer was made within 2 years
after the date of blood collection suggests that the low serum cholesterol is a metabolic consequence rather
than a precursor of the cancer. Our results, which are consistent with the majority of other published studies,
indicate that a low serum cholesterol is not a cause of cancer.
Studies in Western populations have shown that a low serum
cholesterol is associated with an increased risk of cancer but
it is not yet resolved whether this is entirely because
cholesterol is lowered as a metabolic consequence of
undiagnosed cancer, or if, as some studies suggest, there is
also a long-term association between low cholesterol and
cancer. We therefore decided to investigate this using data
from the BUPA study, a prospective study of men attending
a medical screening centre in London.
Subjects and methods
The design of our prospective study has been described
before (Wald et al., 1980, 1986). In summary, the population
that was studied consisted of about 22,000 men aged 35-64
years who attended the British United Provident Association
(BUPA) medical centre in London for a comprehensive
medical examination (including a serum cholesterol
measurement) between 1975 and 1982. The National Health
Service records of these men were flagged and the Office of
Population Censuses and Surveys informed us (up to the end
of April 1986 for this analysis) of cancer notifications by site
(through the National Cancer Registry) and of all deaths by
cause. We here report on the same series of cancer subjects
and controls as was previously used to examine the
association of cancer with serum retinol, vitamin E and beta-
carotene (Wald et al., 1986, 1987, 1988). There were 271
cancer subjects of whom 262 each had two matched
controls and nine each had only one control. The matching
factors were age (within 3 years), date of cholesterol
measurement (within 3 months), smoking status (current
smoker, ex-smoker or life-long non-smoker) and, for current
smokers, the type of smoking (cigarette, cigar or pipe),
amount smoked (within five cigarettes per day, two cigars
per day, one ounce of tobacco per week) and age of starting
to smoke (within five years). Four cases had unknown
cholesterol values, and with their eight controls, had to be
omitted from this report.
Serum cholesterol was measured by the Lieberman
Burchad method (Hunteler & van der Slik, 1972) to mid-
April 1979 and enzymatically thereafter (Allain et al., 1974),
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within a week of the men being seen. The change in method
resulted in a shift of the serum cholesterol distribution: the
mean fell by 0.43mmoll-1, but there was no material
change in the standard deviation. To allow for this,
0.43mmol l- 1 was added to serum cholesterol values
obtained after the change. Relative risks were estimated
using the conditional logistic regression method of Breslow
& Day (1980) which allows for the matched design.
Results
Table I shows the mean cholesterol concentration of subjects
and matched controls, both for all cancer and for the
same specific sites as used in our previous analyses (Wald
et al., 1987), classified according to the interval between
blood collection and the diagnosis of cancer. The mean
serum cholesterol level for all the cancer subjects was similar
to that for their controls (6.66 and 6.72mmol 1-I respectively
(P>0.2)). Subjects whose cancer was diagnosed two or more
years after blood collection also had a similar mean
cholesterol level to their controls (6.79 and 6.68mmol -1
respectively (P>0.2)). However, the mean cholesterol level
was lower in subjects whose cancer was diagnosed before two
years atter the date of blood collection (6.49 in subjects and
6.78mmol I - I in controls (P=0.02)).
Interpretation of the results for individual cancer sites is
limited by the smaller numbers of subjects available.
However, the same pattern of an association with low
cholesterol in the short-term, but not in the long-term, was
apparent in the mean values for a number of the individual
cancer sites (Table I), and there was no evidence that the
sites differed in this regard (statistical test for heterogeneity,
P>0.2).
Table II shows the mean serum cholesterol level in all
cancer subjects and matched controls according to the
interval between blood collection and the diagnosis of
cancer. Among subjects who had blood taken within a year
of diagnosis, the mean serum cholesterol was 0.32mmol -1
(4.7%) lower than among controls (P=0.02). As the interval
increased, the difference diminished and, after three or more
years, the mean serum cholesterol in subjects was in fact
slightly higher (though not significantly so) in subjects than
in controls. This trend was statistically significant (P=0.02).
Table III shows the relative risk of any cancer according
to the quintile of serum cholesterol level and according to
the interval between blood collection and the diagnosis of
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Table I Mean serum cholesterol concentrations in cancer subjects and matched controls according to interval between blood collection and
diagnosis of cancer and according to site of cancer
Interval between blood collection and diagnosis of cancer
Less than 2 years 2 or more years Any time
Mean Mean Mean
Site of cholesterol Difference (s.e.) cholesterol Difference (s.e.) cholesterol Difference (s.e.)
cancer Number (mmoll-1) (mmoll-1) Number (mmoll-1) (mmoll-1) Number (mmoll 1) (mmoll-1)
Lung Subjects 12 6.55 -0.06 (0.39) 37 6.94 +0.21 (0.22) 49 6.84 +0.14 (0.19)
Controls 23 6.61 74 6.73 97 6.70
Colorectal Subjects 10 6.38 -0.31 (0.42) 19 6.84 +0.26 (0.31) 29 6.68 +0.06 (0.25)
Controls 20 6.69 37 6.58 57 6.62
Stomach Subjects 5 6.48 -1.04 (0.60) 7 6.50 -0.38 (0.51) 12 6.50 -0.65 (0.39)
Controls 10 7.52 14 6.88 24 7.15
Bladder Subjects 9 6.65 -0.32 (0.45) 6 6.85 -0.37 (0.55) 15 6.73 -0.34 (0.35)
Controls 17 6.97 12 7.22 29 7.07
Central Subjects 7 5.77 -0.72 (0.51) 10 7.40 +0.42 (0.42) 17 6.73 -0.05 (0.33)
nervous Controls 14 6.49 20 6.98 34 6.78
system
Skin Subjects 39 6.66 -0.06 (0.22) 17 6.83 +0.10 (0.33) 56 6.71 -0.01 (0.18)
Controls 73 6.72 34 6.73 107 6.72
Other Subjects 34 6.41 -0.43 (0.23) 55 6.59 +0.06(0.18) 89 6.52 -0.13 (0.14)
sites Controls 67 6.84 110 6.53 177 6.65
All Subjects 116 6.49 -0.29 (0.13) 151 6.79 +0.11 (0.11) 267 6.66 -0.06 (0.08)
sites Controls 224 6.78 301 6.68 525 6.72
Table II Mean serum cholesterol concentrations in cancer subjects and matched
controls according to interval between blood collection and diagnosis of cancer
Number of Mean cholesterol
Interval between
blood collection Cancer
and diagnosis Cancer subjects Controls Difference (s.e.)a
of cancer subjects Controls (mmoll-1) (mmoll-1) (mmoll-1)
Less than 1 year 89 170 6.50 6.82 -0.32 (0.14)
1-2 years 60 119 6.58 6.74 -0.16 (0.17)
3-4 years 59 118 6.81 6.57 +0.24 (0.18)
5 or more years 59 118 6.84 6.72 +0.12 (0.18)
Any time 267 525 6.66 6.72 -0.06 (0.08)
aTrend with time to diagnosis is statistically significant (P=0.02).
Table III Relative risks of cancer according to cholesterol concentration and interval between blood collection and diagnosis of cancera
Cholesterol
concentration Interval between blood collection and diagnosis of cancer
Less than 2 years 2 or more years Any time
Number of Number of Number of
Mean for
Limits quintile Cancer Relative Cancer Relative Cancer Relative
Quintileb (mmol1-1) (mmoll'1) subjects Controls riskc subjects Controls riskd subjects Controls riskd
1st 2.7-5.8 5.28 34 49 1.37 26 70 0.75 60 119 0.99
2nd 5.8-6.4 6.17 21 32 1.19 31 55 1.08 52 87 1.15
3rd 6.4-6.9 6.70 26 42 1.14 34 58 1.18 60 100 1.18
4th 7.0-7.5 7.27 19 52 0.69 30 57 1.04 49 109 0.88
5th 7.6-11.0 8.25 16 49 0.57 30 61 0.97 46 110 0.81
All 2.7-11.0 6.70 116 224 1.00 151 301 1.00 267 525 1.00
aRelative risks take into account the matched design of the study and are expressed relative to the risk in the 'all' category; bBecause the
original cholesterol levels were taken to the nearest 0.1mmol1-1, the'quintiles' do not contain equal numbers; CTest for trend, P=0.01; dTest
for trend, P>0.2.
cancer (<2 years and 2 years). For those diagnosed earlier
there was a statistically significant declining trend in relative
risk from the lowest to the highest cholesterol quintile, but
this was not the case for those diagnosed later.
In these data, there was no evidence of an association
between serum cholesterol and the age of the subjects and
controls. The mean cholesterol was, on average,
0.1Immol 1 - (s.e. =0.08) higher in current smokers than in
non-smokers, but in current smokers of cigarettes alone,
there was no evidence of an association between cholesterol
and cigarette consumption. Thus the matching for age and
smoking habit were less important in this study on serum
cholesterol than in our previous studies of serum beta-
carotene and vitamin E based on the same series of cancer
subjects and controls (Wald et al., 1987, 1988).
Discussion
In our study the inverse association between serum
cholesterol and cancer that others have found was restricted
to cancers diagnosed less than 2 years after the date of blood938 N.J. WALD et al.
collection. Our data therefore suggest that the low serum
cholesterol was a metabolic consequence, rather than a
precursor, of the cancer. It follows that a lowered serum
cholesterol should not be regarded as a cause of cancer. We
have not been able to consider many sites ofcancer separately
since our study was not large enough to do so.
Most studies, as well as our own, show that the low
cholesterol-cancer association is either entirely confined to
the short-term (a few years) (Hiatt & Fireman, 1986;
Wingard et al., 1984; Salonen, 1982; Wallace et al., 1982;
Thomas et al., 1982; Kromhout et al., 1988) or is substantially
so; any longer-term association being less marked than the
short-term association and no longer statistically significant
(Sherwin et al., 1987; International Collaborative Group,
1982; Keys et al., 1985; Gerhardsson et al., 1986; Sorlie &
Feinleib, 1982). Some studies, however, show a persistent
longer-term association that is of comparable magnitude to
the short-term association which is most apparent with lung
cancer and, in general, is statistically significant (Kagan et al.,
1981; Garcia-Palmieri et al., 1981; Kark et al., 1980; Schatzkin
et al., 1987; Morris et al., 1983). The reason for the discrepancy
is uncertain, but it is unlikely to be due to chance, The fact
that a number of large and well conducted studies show no
long-term association between low serum cholesterol and
cancer at all sites or cancer at individual sites (including lung)
makes it unlikely that the association found in some studies
is causal and suggests that it is due to the effect ofunidentified
confounding factors or other sources of bias present in the
studies concerned or the populations examined.
We would like to thank Dr Jillian Boreham for her assistance in
data processing.
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